Experienced in Autosomal Dominant Partial Epilepsy with Auditory Features

Dr. Samuel A. Goldlust

Neurology
Saint Lukes Physician Group Inc
4401 Wornall Rd, 
Kansas City, MO 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Autosomal Dominant Partial Epilepsy with Auditory Features
Saint Lukes Physician Group Inc
4401 Wornall Rd, 
Kansas City, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Samuel Goldlust is a Neurologist in Kansas City, Missouri. Dr. Goldlust is rated as an Experienced provider by MediFind in the treatment of Autosomal Dominant Partial Epilepsy with Auditory Features. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Goldlust is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Hospital Affiliations
Saint Luke's East Hospital
Saint Luke's South Hospital
St Lukes Hospital Of Kansas City
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

SAINT LUKES PHYSICIAN GROUP INC
4401 Wornall Rd, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Recruiting
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Device, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 1
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Enrollment Status: Suspended
Publish Date: February 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 11 Less Clinical Trials

23 Total Publications

Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Similar Doctors
Distinguished in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Patrick X. Landazuri
Neurology
Distinguished in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Patrick X. Landazuri
Neurology

Kansas University Physicians Inc

10710 Nall Ave, 
Overland Park, KS 
 (8.5 miles away)
913-588-1227
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Landazuri is a Neurologist in Overland Park, Kansas. Dr. Landazuri is rated as a Distinguished provider by MediFind in the treatment of Autosomal Dominant Partial Epilepsy with Auditory Features. His top areas of expertise are Seizures, Epilepsy, Memory Loss, and Partial Seizure. Dr. Landazuri is currently accepting new patients.

Distinguished in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Sreenadha R. Davuluri
Neurology
Distinguished in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Sreenadha R. Davuluri
Neurology
105 Far West Drive, Suite 201, 
St Joseph, MO 
 (50.8 miles away)
816-271-8182
Languages Spoken:
English, Farsi, Hindi, Spanish, Telugu, Urdu
See accepted insurances
Accepting New Patients

Sreenadha Davuluri is a Neurologist in St Joseph, Missouri. Dr. Davuluri is rated as a Distinguished provider by MediFind in the treatment of Autosomal Dominant Partial Epilepsy with Auditory Features. His top areas of expertise are Memory Loss, Progressive Myoclonic Epilepsy, Unverricht-Lundborg Syndrome, and Lafora Disease. Dr. Davuluri is currently accepting new patients.

Advanced in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Utku Uysal
Neurology
Advanced in Autosomal Dominant Partial Epilepsy with Auditory Features
Dr. Utku Uysal
Neurology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.3 miles away)
913-588-7013
Languages Spoken:
English, German, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Utku Uysal is a Neurologist in Kansas City, Kansas. Dr. Uysal is rated as a Distinguished provider by MediFind in the treatment of Autosomal Dominant Partial Epilepsy with Auditory Features. His top areas of expertise are Seizures, Epilepsy, Memory Loss, Autosomal Dominant Partial Epilepsy with Auditory Features, and Deep Brain Stimulation. Dr. Uysal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldlust's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile